Chemistry

Creative Enzymes

Creative Enzymes is a professional and experienced supplier of probiotics. In the past decade, Creative Enzymes mainly provides enzyme-related products and services. With the continuous expansion of business areas and scale, we have set foot in other areas and established a sound probiotic production and supply chain. Based on our high-quality products and services, as well as the unique advantages of large-scale production, our probiotic products are widely favored by industrial customers and scientific research customers.  More information at https://probiotic.creative-enzymes.com/

Probiotics Products

Creative Enzymes uses its expertise in enzyme manufacturing to supply customers enzymes using for life science research and production of medicines, food, alcohol, beer, fruit juice, fabric, paper, leather goods, etc. Our products are used worldwide in academic, commercial, and government laboratories in diverse applications, including basic research, drug discovery, cancer research, infectious disease research, microbiology, and personalized medicine. As a reliable supplier, Creative Enzymes supplies the products of high quality and competitive cost-effectiveness. We cooperate with a large number of satisfied customers in corresponding fields all over the world.  https://www.creative-enzymes.com/

Great Minds Choose Creative Enzymes

Oncotarget

Oncotarget published this trending editorial in Volume 14, entitled, “To be or not to be: the role of CD56 in multiple myeloma" by the researchers from the Department of Internal Medicine, Division of Hematology, College of Medicine, The Ohio State University, Columbus, OH.

DOI - https://doi.org/10.18632/oncotarget.28350 (PDF Download)

Correspondence to - : Francesca Cottini - Francesca.cottini@osumc.edu 

Paper Intro

Optimal management of Multiple Myeloma (MM), a disorder of clonal malignant plasmacells (PCs), is hampered by the lack of strategies to treat specific subsets of patients. Despite genetic, epigenetic, and mutational heterogeneity, every patient still receives similar regimens without accounting for this variability. This can lead to unsatisfactory or short-lasting responses especially in the relapsed settings or in patients with high-risk chromosomal abnormalities such as t(4;14), 1q21+, or deletion(17p) [1]. MM cells express on their surface a variety of antigens, which help to discern normal reactive PCs from malignant MM cells [2]. These antigens are also targets for monoclonal antibodies, bispecific engagers, or chimeric T/NK cellular therapy [3, 4]. Among them, there is CD56 or NCAM1 (Neuronal Cell adhesion molecule 1), a glycoprotein normally present in neurons, Natural Killer (NK), and T cells, but aberrantly expressed in more than seventy percent of patients with MM [5].

Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28350

Keywords - myeloma, targeted therapies, CD56, signaling

About Oncotarget

Oncotarget is a primarily oncology-focused, peer-reviewed, open access journal. Papers are published continuously within yearly volumes in their final and complete form, and then quickly released to Pubmed. On September 15, 2022, Oncotarget was accepted again for indexing by MEDLINE. Oncotarget is now indexed by Medline/PubMed and PMC/PubMed.

To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us:

SoundCloud - https://soundcloud.com/oncotarget
Facebook - https://www.facebook.com/Oncotarget/
Twitter - https://twitter.com/oncotarget
Instagram - https://www.instagram.com/oncotargetjrnl/
YouTube - https://www.youtube.com/OncotargetYouTube
LinkedIn - https://www.linkedin.com/company/oncotarget
Pinterest - https://www.pinterest.com/oncotarget/
Reddit - https://www.reddit.com/user/Oncotarget/

Media Contact
MEDIA@IMPACTJOURNALS.COM
18009220957

To Be or Not to Be: The Role of CD56 in Multiple Myeloma

Oncotarget published this research paper in Volume 14, entitled, “Spleen tyrosine kinase/FMS-like tyrosine kinase-3 inhibition in relapsed/refractory B-cell lymphoma, including diffuse large B-cell lymphoma: updated data with mivavotinib (TAK-659/CB-659)" by the researchers from the Division of Hematology and Oncology, Northwestern University Feinberg School of Medicine and the Robert H. Lurie Comprehensive Cancer Center, Chicago, IL; Department of Haematology, NIHR/UCLH Clinical Research Facility, University College London Hospitals NHS Foundation Trust, London, UK; Drug Development, Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN; Dipartimento di Oncologia ed Ematologia, Ospedale Papa Giovanni XXIII, Bergamo, Italy; Division of Hematology and Oncology, Cancer Therapy and Research Center at University of Texas Health Science Center, San Antonio, TX; Drug Development Unit, Florida Cancer Specialists/Sarah Cannon Research Institute, Sarasota, FL; Department of Medicine, Royal Marsden Hospital, Sutton, Surrey, UK; NIHR Clinical Research Facility, The Christie NHS Foundation Trust and University of Manchester, Manchester Academic Health Science Centre, Manchester, UK; Hematology, Hospital Universitario HM Sanchinarro, Madrid, Spain; IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia “Seràgnoli”, Bologna, Italy; Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale, Università di Bologna, Bologna, Italy; Department of Hematology and Oncology, Houston Methodist Cancer Center, Houston, TX; Oncology Clinical Science, Takeda Development Center Americas, Inc. (TDCA), Lexington, MA; Servei d’Hematologia, Vall d’Hebron Hospital Universitari, Experimental Hematology, Vall d’Hebron Institute of Oncology (VHIO), Vall d’Hebron Barcelona Hospital Campus, Barcelona, Spain; Departament de Medicina, Universitat Autònoma de Barcelona, Bellaterra, Spain; Current affiliation: Division of Hematology and Oncology, Banner MD Anderson Cancer Center, Gilbert, AZ.

DOI - https://doi.org/10.18632/oncotarget.28352

Correspondence to - Leo I. Gordon - l-gordon@northwestern.edu 

Abstract

We report an updated analysis from a phase I study of the spleen tyrosine kinase (SYK) and FMS-like tyrosine kinase 3 inhibitor mivavotinib, presenting data for the overall cohort of lymphoma patients, and the subgroup of patients with diffuse large B-cell lymphoma (DLBCL; including an expanded cohort not included in the initial report).

Patients with relapsed/refractory lymphoma for which no standard treatment was available received mivavotinib 60–120 mg once daily in 28-day cycles until disease progression/unacceptable toxicity.

A total of 124 patients with lymphoma, including 89 with DLBCL, were enrolled. Overall response rates (ORR) in response-evaluable patients were 45% (43/95) and 38% (26/69), respectively. Median duration of response was 28.1 months overall and not reached in DLBCL responders. In subgroups with DLBCL of germinal center B-cell (GCB) and non-GCB origin, ORR was 28% (11/40) and 58% (7/12), respectively. Median progression free survival was 2.0 and 1.6 months in the lymphoma and DLBCL cohorts, respectively. Grade ≥3 treatment-emergent adverse events occurred in 96% of all lymphoma patients, many of which were limited to asymptomatic laboratory abnormalities; the most common were increased amylase (29%), neutropenia (27%), and hypophosphatemia (26%).

These findings support SYK as a potential therapeutic target for the treatment of patients with B-cell lymphomas, including DLBCL.

Trial registration: ClinicalTrials.gov number: NCT02000934.

Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28352

Keywords - Non-Hodgkin’s lymphoma, DLBCL, relapsed/refractory, SYK inhibitor, TAK-659

About Oncotarget

Oncotarget is a primarily oncology-focused, peer-reviewed, open access journal. Papers are published continuously within yearly volumes in their final and complete form, and then quickly released to Pubmed. On September 15, 2022, Oncotarget was accepted again for indexing by MEDLINE. Oncotarget is now indexed by Medline/PubMed and PMC/PubMed.

To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us:

SoundCloud - https://soundcloud.com/oncotarget
Facebook - https://www.facebook.com/Oncotarget/
Twitter - https://twitter.com/oncotarget
Instagram - https://www.instagram.com/oncotargetjrnl/
YouTube - https://www.youtube.com/OncotargetYouTube
LinkedIn - https://www.linkedin.com/company/oncotarget
Pinterest - https://www.pinterest.com/oncotarget/
Reddit - https://www.reddit.com/user/Oncotarget/

Media Contact
MEDIA@IMPACTJOURNALS.COM
18009220957

Mivavotinib for Relapsed/Refractory B-cell Lymphoma (Updated)

Teach Me in 10

Does your vegan schnitzel taste slightly rancid or does your dairy product taste bitter? Does your food unpleasant, when you open the package? This is what chemists call an off-flavor.

This unpleasant effect is stronger with some products than with others, and this is because of the predominantly plant-based origin of the raw materials, which are subject to certain variations and can therefore cause an unpleasant taste. Food chemists need to be able to detect these substances at very low concentrations and find out if they are present in all or just in some products. 

In this episode, we are joined by Petra Gerhards, regional marketing manager for EMEA at Thermo Fisher Scientific. She explains how to detect small concentrations of off-flavors quickly with the Thermo Scientific™ Orbitrap™ MS technology which includes fully automated deconvolution. 

By watching this episode, you will learn about a fully automated workflow for Off Flavor analysis including sample preparation, High-Resolution Mass Spectrometry, Deconvolution and Principal Compound analysis.

Why Vegan Products Don’t Always Taste As You’d Expect

Oncotarget published this research paper in Volume 13, entitled, “Anti-tumor effect of antibody drug conjugate ASP1235 targeting Fms-like tyrosine kinase 3 with venetoclax plus azacitidine in an acute myeloid leukemia xenograft mouse model" by the researchers from Immuno-Oncology, Astellas Pharma Inc., Tsukuba, Ibaraki 305-8585, Japan and Applied Research and Operations, Astellas Pharma Inc., Tsukuba, Ibaraki 305-8585, Japan.

DOI - https://doi.org/10.18632/oncotarget.28331

Correspondence to - Hirofumi Tsuzuki - hirofumi.tsuzuki@astellas.com 

Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28331

Keywords - acute myeloid leukemia (AML), ASP1235, antibody drug conjugate (ADC), venetoclax, azacitidine

About Oncotarget

Oncotarget is a primarily oncology-focused, peer-reviewed, open access journal. Papers are published continuously within yearly volumes in their final and complete form, and then quickly released to Pubmed. On September 15, 2022, Oncotarget was accepted again for indexing by MEDLINE. Oncotarget is now indexed by Medline/PubMed and PMC/PubMed.

To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us:

SoundCloud - https://soundcloud.com/oncotarget
Facebook - https://www.facebook.com/Oncotarget/
Twitter - https://twitter.com/oncotarget
Instagram - https://www.instagram.com/oncotargetjrnl/
YouTube - https://www.youtube.com/OncotargetYouTube
LinkedIn - https://www.linkedin.com/company/oncotarget
Pinterest - https://www.pinterest.com/oncotarget/
Reddit - https://www.reddit.com/user/Oncotarget/

Media Contact
MEDIA@IMPACTJOURNALS.COM
18009220957

Anti-tumor Effect of Antibody Drug With Venetoclax Plus Azacitidine in Acute Myeloid Leukemia

Enzyme labeling, also known as immunoenzymatic technology, is based on the immune reaction. It uses a highly specific immune reaction combined with the efficient catalytic action of enzymes to form a complete set of biological technologies that are highly specific and highly sensitive. https://www.creative-enzymes.com/service/Enzyme-Labelling-Services_358.html

Enzyme Labelling - Creative Enzymes

Alfa Chemistry

Earlier this month, Alfa Chemistry announced the launch of Sodium caprylate, Monobenzone, Titanium acetylacetonate, Bis[2-(2-butoxyethoxy)ethyl]adipate, Poly(3-hydroxybutyrate-co-3-hydroxyvalerate), Polycarbomethylsilane, Ricinoleamidopropyl ethyldimonium ethosulfate, and Potassium 9-Chlorohexadecafluoro-3-Oxanonane-1-Sulfonate. Learn more at https://reagents.alfa-chemistry.com/

Alfa Chemistry New Products Launch, November 2022

In this episode of Teach Me in 10, we are joined by Matt Hammond who is an applications and collaborations manager of protein quantitation at Bio-Rad Laboratories. 
Matt teaches us about the strengths of using a total protein signal as the reference signal in a western lot experiment, as well as how to use Bio-Rad’s Stain Free technology to provide this signal easily and reliably.

Chemistry

Refine By

Keep up to date with all your favourite videos and channels.

Get personalised notifications on new releases and channel content by subscribing to the LabTube eNewsletter.